Mechanistically, pembrolizumab binds to PD-1 and thus shields PD-1–expressing T cells from the interaction with programmed death-ligand 1 (PD-L1), which is commonly expressed on cancer cells to suppress antitumor T cell responses. Here, PDCD1 is linked to cancer.